Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman

December 13, 2010

Mississauga, Ontario, December 13, 2010 /PRNewswire via COMTEX/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Robert A. Ingram, Valeant’s lead independent director, was appointed as Chairman of the Board of Directors, replacing William M. Wells, who has resigned from the Board to pursue other interests.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information: 
Laurie W. Little
949-461-6002
laurie.little@valeant.com